![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Awards Breakthrough Therapy Designation to Kite for KTE-C19
FDA Awards Breakthrough Therapy Designation to Kite for KTE-C19
December 11, 2015
The FDA has awarded breakthrough therapy designation to Kite Pharma its KTE-C19 for treatment of patients with refractory diffuse large B cell lymphoma, primary mediastinal B cell lymphoma and transformed follicular lymphoma.
An investigational therapy, KTE-C19 consists of a patient’s genetically modified T-cells to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the surface of B cell lymphomas and leukemias.
Upcoming Events
-
21Oct